Sign Out
Treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II-IV.
Considerations for use: Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in WHO Class II patients, which may preclude future use as their disease progresses.
